Literature DB >> 21791422

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases.

Anastasia Hadzidimitriou1, Andreas Agathangelidis, Nikos Darzentas, Fiona Murray, Marie-Helene Delfau-Larue, Lone Bredo Pedersen, Alba Navarro Lopez, Antonis Dagklis, Paul Rombout, Kheira Beldjord, Arne Kolstad, Martin H Dreyling, Achilles Anagnostopoulos, Athanasios Tsaftaris, Penelope Mavragani-Tsipidou, Andreas Rosenwald, Maurilio Ponzoni, Patricia Groenen, Paolo Ghia, Birgitta Sander, Theodora Papadaki, Elias Campo, Christian Geisler, Richard Rosenquist, Frederic Davi, Christiane Pott, Kostas Stamatopoulos.   

Abstract

We examined 807 productive IGHV-IGHD-IGHJ gene rearrangements from mantle cell lymphoma (MCL) cases, by far the largest series to date. The IGHV gene repertoire was remarkably biased, with IGHV3-21, IGHV4-34, IGHV1-8, and IGHV3-23 accounting for 46.3% of the cohort. Eighty-four of 807 (10.4%) cases, mainly using the IGHV3-21 and IGHV4-34 genes, were found to bear stereotyped heavy complementarity-determining region 3 (VH CDR3) sequences and were placed in 38 clusters. Notably, the MCL stereotypes were distinct from those reported for chronic lymphocytic leukemia. Based on somatic hypermutation (SHM) status, 238/807 sequences (29.5%) carried IGHV genes with 100% germ line identity; the remainder (569/807; 70.5%) exhibited different SHM impact, ranging from minimal (in most cases) to pronounced. Shared replacement mutations across the IGHV gene were identified for certain subgroups, especially those using IGHV3-21, IGHV1-8, and IGHV3-23. Comparison with other entities, in particular CLL, revealed that several of these mutations were "MCL-biased." In conclusion, MCL is characterized by a highly restricted immunoglobulin gene repertoire with stereotyped VH CDR3s and very precise SHM targeting, strongly implying a role for antigen-driven selection of the clonogenic progenitors. Hence, an antigen-driven origin of MCL could be envisaged, at least for subsets of cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791422     DOI: 10.1182/blood-2011-03-343434

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

Review 1.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

Review 2.  The biology of aging and lymphoma: a complex interplay.

Authors:  Clémentine Sarkozy; Gilles Salles; Claire Falandry
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

Review 3.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 4.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

5.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.

Authors:  Ryan M Young; Tianyi Wu; Roland Schmitz; Moez Dawood; Wenming Xiao; James D Phelan; Weihong Xu; Laurence Menard; Eric Meffre; Wing-Chung C Chan; Elaine S Jaffe; Randy D Gascoyne; Elías Campo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

6.  Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

Authors:  Tiffany Tang; Peter Martin
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

7.  Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders.

Authors:  Ana Henriques; Arancha Rodríguez-Caballero; Ignacio Criado; Anton W Langerak; Wendy G Nieto; Quentin Lécrevisse; Marcos González; Emília Cortesão; Artur Paiva; Julia Almeida; Alberto Orfao
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

Review 8.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

Review 9.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

Review 10.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.